http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 11 Jun 2026 12:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html Thu, 11 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html Thu, 11 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html Thu, 11 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html Thu, 11 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html Thu, 11 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html Thu, 11 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html Thu, 11 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html Thu, 11 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html Thu, 11 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html Thu, 11 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html Thu, 11 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html Thu, 11 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html Thu, 11 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+May+31st%2C+2026/26634470.html Thu, 11 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, confirms that it meets the eligibility criteria for its shares to be held in a PEA-PME account, set forth in Article L.221-32-2 of the French Monetary and Financial Code. </p><p> Consequently, investment in Adocia shares can be made through PEA-PME savings accounts. This scheme is specially designed to encourage investment in small and medium-sized companies, offering tax benefits notably an income tax exemption on gains realized, provided no http://www.streetinsider.com/Press+Releases/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html Wed, 10 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, confirms that it meets the eligibility criteria for its shares to be held in a PEA-PME account, set forth in Article L.221-32-2 of the French Monetary and Financial Code. </p><p> Consequently, investment in Adocia shares can be made through PEA-PME savings accounts. This scheme is specially designed to encourage investment in small and medium-sized companies, offering tax benefits notably an income tax exemption on gains realized, provided no http://www.streetinsider.com/Press+Releases/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html Wed, 10 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, confirms that it meets the eligibility criteria for its shares to be held in a PEA-PME account, set forth in Article L.221-32-2 of the French Monetary and Financial Code. </p><p> Consequently, investment in Adocia shares can be made through PEA-PME savings accounts. This scheme is specially designed to encourage investment in small and medium-sized companies, offering tax benefits notably an income tax exemption on gains realized, provided no http://www.streetinsider.com/Press+Releases/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html Wed, 10 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, confirms that it meets the eligibility criteria for its shares to be held in a PEA-PME account, set forth in Article L.221-32-2 of the French Monetary and Financial Code. </p><p> Consequently, investment in Adocia shares can be made through PEA-PME savings accounts. This scheme is specially designed to encourage investment in small and medium-sized companies, offering tax benefits notably an income tax exemption on gains realized, provided no http://www.streetinsider.com/Press+Releases/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html Wed, 10 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, confirms that it meets the eligibility criteria for its shares to be held in a PEA-PME account, set forth in Article L.221-32-2 of the French Monetary and Financial Code. </p><p> Consequently, investment in Adocia shares can be made through PEA-PME savings accounts. This scheme is specially designed to encourage investment in small and medium-sized companies, offering tax benefits notably an income tax exemption on gains realized, provided no http://www.streetinsider.com/Press+Releases/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html Wed, 10 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, confirms that it meets the eligibility criteria for its shares to be held in a PEA-PME account, set forth in Article L.221-32-2 of the French Monetary and Financial Code. </p><p> Consequently, investment in Adocia shares can be made through PEA-PME savings accounts. This scheme is specially designed to encourage investment in small and medium-sized companies, offering tax benefits notably an income tax exemption on gains realized, provided no http://www.streetinsider.com/Press+Releases/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html Wed, 10 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, confirms that it meets the eligibility criteria for its shares to be held in a PEA-PME account, set forth in Article L.221-32-2 of the French Monetary and Financial Code. </p><p> Consequently, investment in Adocia shares can be made through PEA-PME savings accounts. This scheme is specially designed to encourage investment in small and medium-sized companies, offering tax benefits notably an income tax exemption on gains realized, provided no http://www.streetinsider.com/Press+Releases/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html Wed, 10 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, confirms that it meets the eligibility criteria for its shares to be held in a PEA-PME account, set forth in Article L.221-32-2 of the French Monetary and Financial Code. </p><p> Consequently, investment in Adocia shares can be made through PEA-PME savings accounts. This scheme is specially designed to encourage investment in small and medium-sized companies, offering tax benefits notably an income tax exemption on gains realized, provided no http://www.streetinsider.com/Business+Wire/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html Wed, 10 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, confirms that it meets the eligibility criteria for its shares to be held in a PEA-PME account, set forth in Article L.221-32-2 of the French Monetary and Financial Code. </p><p> Consequently, investment in Adocia shares can be made through PEA-PME savings accounts. This scheme is specially designed to encourage investment in small and medium-sized companies, offering tax benefits notably an income tax exemption on gains realized, provided no http://www.streetinsider.com/Business+Wire/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html Wed, 10 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, confirms that it meets the eligibility criteria for its shares to be held in a PEA-PME account, set forth in Article L.221-32-2 of the French Monetary and Financial Code. </p><p> Consequently, investment in Adocia shares can be made through PEA-PME savings accounts. This scheme is specially designed to encourage investment in small and medium-sized companies, offering tax benefits notably an income tax exemption on gains realized, provided no http://www.streetinsider.com/Business+Wire/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html Wed, 10 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, confirms that it meets the eligibility criteria for its shares to be held in a PEA-PME account, set forth in Article L.221-32-2 of the French Monetary and Financial Code. </p><p> Consequently, investment in Adocia shares can be made through PEA-PME savings accounts. This scheme is specially designed to encourage investment in small and medium-sized companies, offering tax benefits notably an income tax exemption on gains realized, provided no http://www.streetinsider.com/Business+Wire/ADOCIA+Confirms+its+Eligibility+for+the+PEA%E2%80%91PME+Scheme/26628727.html Wed, 10 Jun 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126